Skip to content
Great Science. Great Medicine.
ChemoCentryx Logo
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Partnering
    • Contact Us
  • Pipeline
    • Overview
    • Orphan and Rare Diseases
    • Chronic Kidney Disease
    • Immuno-Oncology and Other Therapeutic Areas
      • CCX872
      • Preclinical Candidates
    • Other Inflammatory and Autoimmune Diseases
      • Vercirnon
      • CCX507
      • Th17 Driven Diseases and CCR6
  • Diseases
    • Orphan and Rare Diseases
    • Chronic Kidney Disease
    • Immuno-Oncology
    • Other Inflammatory and Autoimmune Diseases
  • Science
  • Investors
    • Overview
    • News Releases
    • Events & Presentations
    • Financials & Filings
      • SEC Filings
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • Management Team
      • Board of Directors
      • Committee Composition
    • Investor FAQs
    • Contact Us
  • Careers
    • Culture
    • Benefits
    • Job Postings
HomepageEddy Mejia2019-11-25T21:09:32+00:00
  • A New Approach.  A Better Approach.
    LEARN MORE ABOUT OUR SCIENCE
  • People Deserve Better Medicine
    SHARE OUR PASSION
  • Not Just a Longer Life, a Better Life.
    LEARN MORE
  • A New Approach.  A Better Approach.
    LEARN MORE ABOUT OUR SCIENCE
  • People Deserve Better Medicine
    SHARE OUR PASSION
  • Not Just a Longer Life, a Better Life.
    LEARN MORE

Positive topline data from pivotal Phase III ADVOCATE trial demonstrates avacopan’s superiority over standard of care in ANCA-associated vasculitis

Learn about LUMINA, a clinical study evaluating CCX140 in Focal Segmental Glomerulosclerosis (FSGS) with and without Nephrotic Syndrome.

Learn about ACCOLADE, a clinical research study for people with C3 glomerulopathy.
RECENT NEWS:

NOW ENROLLING:
.A Phase 3 clinical trial to evaluate the safety and efficacy of avacopan in patients with ANCA-vasculitis »

Clinical study evaluating CCX140 in Focal Segmental Glomerulosclerosis (FSGS) with and without Nephrotic Syndrome – Now Enrolling.
RECENT NEWS:
ChemoCentryx to Present at Three Upcoming Investor Conferences »

People Deserve Better Medicine

At ChemoCentryx, we believe our patients deserve more than the standard of care available today. So, we are developing our broad portfolio of new medicines using a novel approach to better provide patients with safe, convenient and more effective therapies.

We are developing tomorrow’s standard of care.

Learn more

Not Just a Longer Life, a Better Life

People suffering from serious medical conditions want more than incremental improvements. Like all of us, they want to live longer, more enjoyable lives. That’s why when others say, “This is the best we can do,” we say, “We can do better.”

We are developing a better way to treat disease.

Share our passion

A New Approach. A Better Approach.

Our vision is simple. We believe that a targeted biological system—the chemoattractant network—is the key to longer, better lives for thousands of people suffering from serious disease. And we intend to deliver that quality of life to patients through a passion for great science.

Our great science leads to great medicine.

Learn more

COMPANY

  • Overview
  • Management Team
  • Board of Directors
  • Partnering
  • Contact Us

PIPELINE

  • Overview
  • Orphan and Rare Diseases
  • Chronic Kidney Disease
  • Immuno-Oncology and Other Therapeutic Areas
  • Other Inflammatory and Autoimmune Diseases

Diseases

  • Orphan and Rare Diseases
  • Chronic Kidney Disease
  • Immuno-Oncology
  • Other Inflammatory and Autoimmune Diseases

SCIENCE

INVESTORS

Careers

  • Culture
  • Benefits
  • Job Postings

CONTACT INFORMATION

850 Maude Avenue
Mountain View, CA 94043

Phone: +1.650.210.2900

Fax: +1.650.210.2910

Email: info@chemocentryx.com

© ChemoCentryx, Inc. | Legal and Privacy